10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it...
Neuroscience
MYndspan Appoints Holmusk Founder and CEO Nawal Roy as Strategic Advisor
Following momentum from its Crowdcube campaign and investment from EMOTIV, MYndspan is deepening its commitment to evidence-based brain health LONDON,...
Weekly Recap: 15 Health Press Releases You Need to See
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Google Cloud's commitment to AI-powered...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting...
Glass House Brands Announces Hemp Research and Development Agreement with the University of California, Berkeley
LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")...
AFFOA Names Nuream and Z-Polymers the New Awardees of the Product Accelerator for Advanced Fabrics 2.0
CAMBRIDGE, Mass., April 8, 2025 /PRNewswire/ -- Advanced Functional Fabrics of America, Inc. (AFFOA) proudly announces Nuream and Z-Polymers as...
Cala Presents Multiple Clinical Studies Demonstrating Impact of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients at the American Academy of Neurology (AAN)
SAN MATEO, Calif., April 7, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round...
Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition
Jasmine Eyal, Age 16, of Singapore, Receives Top Honors and $400,000 in Education Prizes for her Original Video Explaining Mechanogenetic...
University of Arizona Study Finds Openwater’s Open-LIFU 2.0 Device Achieves Significant Depression Symptom Reduction After Less Than Two Hours Total Treatment Time
Clinical Trial Utilizing Low-Intensity Transcranial Focused Ultrasound Pulses to Key Brain Region Shows Notable Reduction in Negative Thoughts, Improved Well-being,...
Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting
Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater...
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the...
NETRAMARK AND WORLDWIDE CLINICAL TRIALS ANNOUNCE AGREEMENT TO TRANSFORM CLINICAL TRIAL DESIGN WITH AI-POWERED PRECISION
TORONTO, April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial...
SPARK NS Selects Eight Projects to Receive Aggregate Funding of Up to $16 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic
Academic research teams of selected projects participate in a translational research program that eliminates barriers that prevent promising discoveries from...
MedRhythms Announces Availability of Movive™ for Parkinson’s Disease (PD) for Veterans
PORTLAND, Maine, April 2, 2025 /PRNewswire/ -- MedRhythms today announced that Movive™, the company's neurorehabilitation system to support gait rehabilitation and...
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
NeuroQuiet Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness & Safety
NeuroQuiet Reviews NeuroQuiet VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a market flooded with hearing supplements...
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press...
Alzheimer’s Early Detection Tests Using Video Games Could Be As Effective as Blood Tests and Boost Clinical Trials
Tests Were Created by Rutgers-Newark Researchers NEWARK, N.J., March 27, 2025 /PRNewswire/ -- Alzheimer's early detection tests using video games developed...
Linus Health to Present New Research Findings at Leading Alzheimer’s and Parkinson’s Conference
AD/PD™ 2025 to feature presentations on Linus Health's digital cognitive health assessments, plus attendees can learn more about company's recent...
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039,...